在多发性骨髓瘤中,KDM6A调节免疫反应基因
Daphné Dupéré-Richer1, Alberto Riva2, Benjamin G Barwick3
1Division of Hematology/Oncology, University of Florida Health Cancer Center, University of Florida, Gainesville, FL.
Blood
|July 24, 2024
概括
氨酸脱甲基酶6A (KDM6A) 通过调节多发性骨髓瘤中的免疫基因来抑制瘤. 恢复质子乙化可以使KDM6A缺乏的瘤重新敏感于免疫攻击.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 在氨酸27 (H3K27) 脱甲基酶,氨酸脱甲基酶6A (KDM6A) 中的组素H3在各种癌症中起着瘤抑制作用,包括多发性骨髓瘤 (MM).
- 了解KDM6A在MM病变发生中的作用对于开发向疗法至关重要.
研究的目的:
- 为了研究KDM6A在MM细胞中的全基因组结合.
- 阐明KDM6A调节免疫基因和瘤抑制功能的机制.
- 探索KDM6A缺乏MM的治疗策略.
主要方法:
- 创建具有破坏KDM6A和标记内源KDM6A的同源MM细胞系.
- 全基因组染色体免疫沉 (ChIP) 分析以确定KDM6A结合部位.
- 分析基因组蛋白修饰 (H3K27ac,H3K27me3) 和基因表达.
- 在Kdm6a缺乏的小鼠模型中评估瘤生长和免疫细胞透.
主要成果:
- KDM6A与参与免疫识别和细胞因子信号传递的基因结合.
- KDM6A直接结合并激活NLRC5和CIITA,这是主要组织相容性复合体 (MHC) 基因的关键调节者.
- KDM6A损失导致增强剂的H3K27乙化减少,基因体中的H3K27三甲基化增加,以及基因表达的减少.
- 抑制HDAC3可以恢复KDM6A缺乏细胞中的MHC表达.
- 在体内,Kdm6a的丧失促进瘤生长,并减少T细胞透.
结论:
- KDM6A是多发性骨髓瘤中免疫基因表达的关键调节者.
- 向组织酸酶化通路,例如使用HDAC3抑制剂,可以恢复KDM6A缺乏瘤的免疫性.
- KDM6A的瘤抑制功能与其在维持免疫监测中的作用有关.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K


